ReviewPulmonary circulation2022
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.
Review in Pulmonary circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review.BMJ open respiratory research · 2024Pooled it
- Smoking-Related Clinical and Molecular Abnormalities in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension.Pulmonary circulation · 2026Article
- Quantification of chronic vascular remodeling in sickle cell disease.European radiology · 2026Article
- Article
- Development and internal validation of a nomogram to predict pulmonary hypertension in fibrosing interstitial lung diseases.BMC pulmonary medicine · 2026Article
- Pulmonary hypertension optimal screening in interstitial lung disease (PHOS-ILD): a scoring system for the detection of pulmonary hypertension in patients with interstitial lung disease.Frontiers in medicine · 2026Article
- Latin American expert opinion paper on the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease.Frontiers in medicine · 2026Article
- Pulmonary Hypertension Drives Prognosis in Idiopathic Pulmonary Fibrosis: Insights from the European IPF Registry.Journal of clinical medicine · 2025Article
- Real-World Comparison of Patients With PH-ILD Initiating Inhaled Treprostinil Versus Patients Who Remain Untreated.Pulmonary circulation · 2025Article
- Development and Validation of a Scoring System for Prediction of Tolerance to Inhaled Treprostinil in Patients with PAH or PH-ILD.Journal of clinical medicine · 2025Article
- Study Design and Rationale for the PHINDER Study: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection.Pulmonary therapy · 2025Article
- Level 3 Cardiopulmonary Exercise Testing to Guide Therapeutic Decisions in Non-Severe Pulmonary Hypertension with Lung Disease.Life (Basel, Switzerland) · 2025Article
- Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease.Pulmonary circulation · 2025Review
- Physician perspectives on pulmonary hypertension in ILD: results of a cases-based survey.BMC pulmonary medicine · 2025Article
- Haemodynamics and post-exercise recovery response in COPD-PH and ILD-PH: An appraisal.Lung India : official organ of Indian Chest Society · 2025Article
- Pulmonary Hypertension-Related Interstitial Lung Disease: An Expert Opinion with a Real-World Approach.Biomedicines · 2025Article
- Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).Journal of clinical medicine · 2025Review
- Article
- Right Heart Catheterization Accurately Diagnoses Pulmonary Hypertension in Patients With Interstitial Lung Disease: Results From a Long-Term Cohort Study.Pulmonary circulation · 2025Article
- Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.Journal of managed care & specialty pharmacy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 16 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) has been linked to worse outcomes in chronic lung diseases. The presence of PH in the setting of underlying Interstitial Lung Disease (ILD) is strongly associated with decreased exercise and functional capacity, an increased risk of hospitalizations and death. Examining the scope of this issue and its impact on patients is the first step in trying to define a roadmap to facilitate and encourage future research in this area. The aim of our working group is to strengthen the communities understanding of PH due to lung diseases and to improve the care and quality of life of affected patients. This introductory statement provides a broad overview and lays the foundation for further in-depth papers on specific topics pertaining to PH-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.